Welcome to our dedicated page for BeOne Medicines news (Ticker: ONC), a resource for investors and traders seeking the latest updates and insights on BeOne Medicines stock.
BeOne Medicines Ltd. (ONC) generates a steady flow of oncology news that reflects its focus on hematology and solid tumors. As a Switzerland‑domiciled global oncology company with listings on NASDAQ, the Hong Kong Stock Exchange and the STAR Market in Shanghai, BeOne regularly issues updates on clinical data, regulatory milestones, financial performance and corporate developments.
Investors and healthcare professionals following ONC news will see frequent announcements related to B‑cell malignancies, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The company highlights new data for its BTK inhibitor BRUKINSA, including long‑term results from Phase 3 trials such as SEQUOIA and ALPINE, as well as patient‑reported outcomes and guideline updates. News also covers sonrotoclax, an investigational BCL2 inhibitor, with items on FDA Breakthrough Therapy Designation, Priority Review for relapsed or refractory MCL, and clinical results in CLL and other B‑cell cancers. Updates on BTK degrader BGB‑16673 from the CaDAnCe clinical program appear alongside these hematology releases.
On the solid tumor side, BeOne’s news includes Phase 3 trial results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2‑positive gastroesophageal adenocarcinoma, as well as regulatory plans based on these data. Additional releases describe TEVIMBRA’s expanding indications and BGB‑B2033’s FDA Fast Track Designation in hepatocellular carcinoma. Financial news items provide quarterly revenue, product sales trends for BRUKINSA and TEVIMBRA, cash flow metrics and updated guidance, while corporate updates cover conference presentations, research milestones and agreements such as the IMDELLTRA royalty purchase arrangement with Royalty Pharma.
For users tracking ONC, this news stream offers insight into BeOne’s evolving hematology and solid tumor portfolios, its regulatory interactions in major markets and its stated goal of broadening patient access to cancer therapies. Bookmarking the ONC news page on Stock Titan allows readers to follow company press releases, clinical milestones and financial disclosures in one place.
BeOne Medicines (Nasdaq: ONC) reported new EHA 2026 data from its hematology franchise, including BTK degrader tacabrutideg and the all-oral BRUKINSA plus BEQALZI (ZS) combination.
Tacabrutideg showed high response rates and manageable safety in heavily pretreated and BTK inhibitor–naïve B‑cell cancers, while ZS achieved high complete response and uMRD rates across treatment‑naïve and relapsed/refractory CLL and MCL.
BeOne Medicines (Nasdaq: ONC) reported long-term Phase 3 and real‑world data for BRUKINSA in CLL/SLL, including patients aged 80+.
In SEQUOIA patients ≥80, ORR was 100%, 72‑month PFS 63.8% and OS 75.9%, with safety consistent with prior data. Broader 78‑month SEQUOIA results showed PFS 71.8% for BRUKINSA vs 31.0% for bendamustine‑rituximab. Real‑world analyses across more than 250,000 patients linked BRUKINSA to longer time to next treatment, improved survival versus other BTK inhibitors, and lower one‑year atrial fibrillation rates.
BeOne Medicines (Nasdaq: ONC) reported new ASCO 2026 data across three solid tumor programs in breast, gynecologic and gastrointestinal cancers, plus an investor webcast.
Key updates include strong overall response rates and generally manageable safety profiles for CDK4 inhibitor BGB-43395, B7-H4 ADC BG‑C9074 and GPC3x4‑1BB bispecific BGB‑B2033, with pivotal trials and expansion plans underway.
BeOne Medicines (Nasdaq: ONC) reported 78‑month SEQUOIA data for BRUKINSA in first‑line CLL/SLL at ASCO 2026, showing 78‑month PFS of 71.8% vs 31.0% with bendamustine‑rituximab and favorable PFS2 and TTNT.
Real‑world datasets (>250,000 patients) associated BRUKINSA with longer TTNT, improved overall survival, and lower atrial fibrillation rates than other BTK inhibitors. The BRUKINSA plus sonrotoclax (ZS) combo achieved 100% ORR, 59.5% CR, 98.8% uMRD4 and 92.9% uMRD in TP53‑mutated/del(17p) CLL, with median 4.5‑month time to uMRD4 and no progression at the Phase 2 dose.
BeOne Medicines (Nasdaq: ONC) reported Phase 3 HERIZON-GEA-01 results in HER2+ gastroesophageal adenocarcinoma. ZIIHERA plus TEVIMBRA and chemotherapy achieved median overall survival of 26.4 months versus 19.2 months with trastuzumab plus chemotherapy, with consistent benefit across PD-L1 subgroups and no new safety signals.
The FDA accepted a supplemental BLA for TEVIMBRA with priority review, and China’s CDE accepted sBLAs for ZIIHERA and TEVIMBRA in first-line advanced/metastatic HER2+ GEA.
BeOne Medicines (NASDAQ: ONC), a global oncology company, will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Management will join a fireside chat at 10:00 a.m. EDT.
A live webcast and archived replay will be available via the investors section of the company website.
BeOne Medicines (Nasdaq: ONC) announced acceptance of 60+ oncology abstracts for presentation at ASCO 2026 and EHA 2026, spanning CLL, B‑cell malignancies and multiple solid tumors.
Highlights include long-term BRUKINSA CLL data, next‑generation BTK degrader BGB‑16673, sonrotoclax combinations, and early‑stage assets BGB‑43395, BG‑C9074, BGB‑B2033, TEVIMBRA, ZIIHERA and ociperlimab, plus a June 1, 2026 investor webcast.
BeOne Medicines (Nasdaq: ONC) launched One Save Changes Everything, a global cancer care awareness campaign linking the focus of soccer goalkeeping to key moments in cancer research, treatment, and support. The initiative features goalkeeper Tim Howard, international goalkeepers, and a $300,000 community commitment.
BeOne will fund soccer mini-pitches near cancer centers with the U.S. Soccer Foundation and convert employee volunteer hours into charitable dollars, engaging over 12,000 colleagues across six continents to support families affected by cancer.
BeOne Medicines (Nasdaq: ONC) received U.S. FDA accelerated approval for BEQALZI (sonrotoclax), the first and only BCL2 inhibitor for adult relapsed/refractory mantle cell lymphoma after at least two prior systemic therapies including a BTK inhibitor.
Approval is based on Phase 1/2 data showing 52% ORR, 16% CR, median DOR 15.8 months, and generally well-tolerated safety; continued approval depends on the ongoing CELESTIAL-RRMCL confirmatory trial.
BeOne Medicines (NASDAQ: ONC) reported Q1 2026 total revenue of $1.513 billion, up 35% year‑over‑year, driven by BRUKINSA global revenues of $1.1 billion (up 38%). GAAP diluted earnings per ADS were $1.96; adjusted diluted EPS were $3.24. Gross margin was 89% on a GAAP basis.
The company raised full‑year 2026 revenue guidance to $6.3–$6.5 billion and reiterated operating expense guidance of $4.7–$4.9 billion.